Pfizer Reports 12.3 Percent Weight Loss in Mid-Stage Trial for Experimental Obesity Drug PF’3944

Pfizer has released data from a mid-stage clinical trial indicating that its experimental obesity treatment, PF’3944, led to weight loss of up to 12.3% over a 28-week period. The findings mark a significant step in the company’s efforts to expand its presence in obesity treatment following its acquisition of Metsera. Analysts at BMO Capital Markets noted that Pfizer appears to be advancing rapidly in the field of obesity drug development.

The trial results come as part of Pfizer’s broader strategy to compete in the growing market for weight-loss treatments. The reported weight reduction was observed among patients treated with PF’3944 during the study, though further details on patient demographics or specific trial conditions were not disclosed. These findings position Pfizer alongside other pharmaceutical companies actively pursuing advancements in obesity therapies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 3, 2026

Author

GOAI